<DOC>
	<DOCNO>NCT02191891</DOCNO>
	<brief_summary>Part A : To determine maximum tolerate dose ( MTD ) and/or recommend phase II dose ( RP2D ) BI836845 combination afatinib patient non-small cell lung cancer progression follow prior treatment ( EGFR TKI platinum-based chemotherapy ) . Part B : To evaluate early anti-tumour activity BI836845 combination afatinib patient EGFR mutant non-small cell lung cancer progression follow prior irreversible EGFR TKIs . Part A B : To evaluate safety pharmacokinetics BI 836845 combination afatinib patient non-small cell lung cancer</brief_summary>
	<brief_title>BI 836845 Plus Afatinib Patients With Epidermal Growth Factor Receptor ( EGFR ) Mutant Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Inclusion criterion : Aged 18 year old Pathologically confirm advanced and/or metastatic stage IIIb/IV nonsmall cell carcinoma lung Activating EGFR mutation ( exon 19 deletion , L858R , G719X , L861X ) Presence EGFR activate mutation absence EGFR T790M tumour associate late disease progression . Only applicable Part B Must adequate fresh archival tumour tissue late disease progression immediately prior study entry Part A : Progression disease ( RECIST 1.1 ) continuous treatment single EGFR TKI histology adenocarcinoma without prior EGFR TKI treatment : progression disease ( RECIST v1.1 ) platinumbased chemotherapy . Part B : Progression disease ( RECIST v1.1 ) continuous treatment single agent second generation irreversible EGFR TKI ( e.g . afatinib dacomitinib ) TKIfree period &lt; = 30 day prior study treatment . No intervene systemic therapy cessation EGFR TKI study treatment Patient must measurable disease per RECIST 1.1 present tumour biopsy late disease progression Eastern Cooperative Oncology Group ( ECOG ) performance score 0 1 Life expectancy &gt; = 3 month Fasting plasma glucose &lt; 8.9 mmol/L ( &lt; 160mg/dL ) HbA1C &lt; 8 % Adequate organ function Recovered previous therapy relate toxicity &lt; = Grade 1 study entry ( except stable sensory neuropathy &lt; = Grade 2 alopecia ) Written informed consent consistent ICHGCP guideline local regulation No know potentially targetable mutation IGF signal pathway EGFR available treatment potentially targetable mutation Exclusion criterion : For patient treat afatinib : last treatment reduce dose assign dose level ( Part A ) last treatment reduce dose 30 mg/day ( Parts A B ) Patient whose disease progress insufficient dose EGFR TKI immediately prior study opinion investigator More 2 prior EGFR TKI treatment regimens Part B Chemotherapy , biological therapy investigational agent ( except EGFR TKIs ) within 4 week Use previous EGFR TKIs except afatinib within 3 day Radiotherapy within 4 week prior start study treatment Active brain subdural metastasis Meningeal carcinomatosis . Major surgery ( judge investigator ) within 4 week Known hypersensitivity afatinib , monoclonal antibody Prior severe infusionrelated reaction monoclonal antibody History presence clinically relevant cardiovascular abnormality Female patient childbearing potential ( see Section 4.2.2.3 ) male able father child Any history concomitant condition , opinion investigator comply study interfere evaluation efficacy safety test drug Previous concomitant malignancy sit , except effectively treat nonmelanoma skin cancer , carcinoma situ cervix , ductal carcinoma situ effectively treat malignancy remission 3 year consider cure . Disease consider investigator rapidly progress life threaten extensive symptomatic visceral disease include hepatic involvement pulmonary lymphangitic spread tumour ( subject intend urgent chemotherapy ) Requiring treatment prohibit concomitant medication Known preexist interstitial lung disease ( ILD ) Any history presence poorly control gastrointestinal disorder could affect absorption study drug Active hepatitis B infection active hepatitis C infection and/or know HIV carrier . Previous treatment agent target insulin like growth factor ( IGF ) signal pathway . Previous treatment EGFR TKI document either reversible irreversible ( Part B ) Part B : Prior treatment third generation irreversible EGFR TKI ( e.g . AZD9291 CO1686 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>